Louisiana Sheriffs Pension & Relief Fund v. Cardinal Health, Inc.

CourtDistrict Court, S.D. Ohio
DecidedJune 19, 2020
Docket2:19-cv-03347
StatusUnknown

This text of Louisiana Sheriffs Pension & Relief Fund v. Cardinal Health, Inc. (Louisiana Sheriffs Pension & Relief Fund v. Cardinal Health, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Louisiana Sheriffs Pension & Relief Fund v. Cardinal Health, Inc., (S.D. Ohio 2020).

Opinion

FILER RICHARD ts □□□□ CLERN O° □□□□□ UNITED STATES DISTRICT COURT bis □ SOUTHERN DISTRICT OF OHIO B20 JUN IS PH □□ 13 EASTERN DIVISION U4 Deter □□ Me LES □□□□ LOUISIANA SHERIFFS’ PENSION & my TO Seber RELIEF FUND, Individually and on Behalf of All Others Similarly Situated, Plaintiff, Case No. 2:19-CV-3347 JUDGE EDMUND A. SARGUS, JR. v. Magistrate Judge Elizabeth A. Preston Deavers CARDINAL HEALTH, INC.,, et al, Defendants.

OPINION AND ORDER This class action arises from several lawsuits that allege securities fraud claims against Defendant Cardinal Health, Inc., ef a/.. The instant matter is before the Court for consideration of a Motion for Appointment as Lead Plaintiff and Approval of Selection of Lead Counsel (ECF No. 12) filed by Plaintiff Louisiana Sheriffs’ Pension & Relief Fund, Movant City of Fort Lauderdale General Employees Retirement System and Movant Houston Municipal Employees Pension System (collectively, “Public Pension Funds”) as well as a Motion to Appoint Counsel and for Appointment as Lead Plaintiff (ECF No, 13) filed by Movant 1199 SEIU Health Care Employees Pension Fund (“1199 SEYU”). The requisite responses and replies have been filed, and the instant matter is ripe for review. For the reasons that follow, 1199 SETU’s Motion to Appoint Counsel and for Appointment as Lead Plaintiffis GRANTED (ECF No. 13), and Public Pension Funds’ Motion for Appointment as Lead Plaintiff and Approval of Selection of Lead Counsel is DENIED. (ECF No. 12). Accordingly, 1199 SEIU is APPOINTED Lead Plaintiff, and Robbins Geller Rudman & Down LLP is APPOINTED Lead Counsel.

A. Background The securities class action in this case was initiated on behalf of individuals and entities who, between March 2, 2015 and May 2, 2018 (the “Class Period”), purchased Cardinal Health, Inc. (“Cardinal”) common stock. (the “Class”) (ECF No. 1 at { 1). The Class alleges that Cardinal and five of its senior executive officers (“Defendants”) engaged in conduct that violated the Securities Exchange Act of 1934. (The “1934 Act”) and the rules promulgated therefrom. (/@.). Cardinal is an integrated and global distributor of drugs, medical devices and health care services based in Dublin, Ohio, and it has publicly traded common stock on the New York Stock Exchange under the stock ticker CAH. Ud. at 2, 9 & 16). The company operates through two segments: Pharmaceutical and Medical. (/d. at { 16). Cardinal’s Medical segment offers low-tech and low-margin products which include laboratory equipment, gloves and surgical apparel, and, historically, hospitals, ambulatory surgery centers, clinical laboratories, and other health care providers have formed. U/d.). In the last decade, Cardinal has expanded its Medical segment through numerous acquisitions. (/d. at § 17). The Class Period began on March 2, 2015 when Cardinal announced that it would acquire Cordis Corp. (“Cordis”). Ud. at J 17-18). Cordis is a global manufacturer and distributor of interventional cardiology devices and endovascular solutions. (/d.). The company is owned by Ethicon, Inc. which is a wholly-owned Johnson and Johnson subsidiary, and Cardinal acquired Cordis for approximately $1.944 billion dollars to broaden its medical products portfolio and facilitate its global expansion strategy. (/d. at | 17-20). The following claims are made in the Complaint. Cardinal announced that the acquisition would add brand name stents and catheters to its proffered medical products and provide an entry

into higher margin cardiovascular markets. (/d@. at J 19). Cardinal also announced that the acquisition would create a global footprint and platform for future growth through leverage of its existing product line and cross-selling opportunities that would arise from new markets. (/d. at f 20). At the time, these announcements synced with Cordis’ global operations which were taking place in China, Japan, Germany, Italy, France, Brazil, and the United Kingdom. (/d. at 7 18 & 20). In that same vein, Cordis had reported annual sales of approximately $780 million in 2014 which were split between its cardiology and endovascular products. (/d.). According to the Complaint, the acquisition was finalized on October 4, 2015. (Ud. at { 22). From the date of acquisition until the fall of 2017, Defendants consistently stated that the integration of the two companies would result in superior operating efficiencies. (ad. at 26-48). Yet, on August 2, 2017, Cardinal issued an earnings report for its fourth quarter and fiscal year 2017 that fell short of expectations, and the company lowered its earnings projections for fiscal year 2018. (/d. at $50). Cardinal attributed these shortcomings to disappointing earnings on “higher- than-planned write-offs for excess inventory” at Cordis, explaining that the cost of moving manufacturing and standing up Cordis’s back-office services had been more expensive than originally modeled. (/d.). That same day, during Cardinal’s earnings call, Defendants stated that “much of the heavy lifting is behind us” and that the business was “getting some commercial momentum,” including “solid sales growth in Asia Pacific, Latin America and Europe.” Jd. The Complaint makes further allegations that Cardinal’s stock fell over eight percent following these disclosures. (/d, at ] 51). Thereafter, Cardinal announced lower-than-expected earnings on May 3, 2018 for the third quarter of fiscal year 2018, attributing the decrease to “unanticipated disappointing performance from our Cordis business.” (/d. at 157). As a result, the company’s share price dropped again, this time over twenty-one percent. (/d. at ] 60). On August 6, 2018, Cardinal released its fourth quarter and fiscal year 2018 results which revealed that annual operating profits jettisoned from $2.120

billion in 2017 to $126 million in 2018. (/d. at { 61). Cardinal explained that this decline was mainly the result of a $1.4 billion non-cash goodwill impairment that it acquired to mitigate the “inventory and cost challenges within [the] Cordis business.” (/d.). Cardinal also announced in its 2018 annual report that it had increased its reserves of excess and obsolete inventory from $76 million to $147 million in light of new discoveries concerning Cordis’ inventory. (/d.). Cardinal’s CEO, Kaufmman, announced that if Cardinal had initiated its IT platform earlier, it would have written off the inventory sooner. (7d. at 58). The write offs that resulted reduced Cardinal’s Medical division profits and raised Cardinal’s effective tax rate from 32.3 % to 45.1 %, representing an increase that was 7% higher than what was projected the previous quarter. (/d.). The defective product lines caused Cordis to encounter losses in foreign jurisdictions which prevented Cardinal from acquiring certain tax benefits. (/d.). Further, Cardinal announced that its lack of “visibility” into Cordis’ overseas operations created inefficiencies at Cordis manufacturing plants.

Defendants stated that Cardinal “needfed to put] several tools in place” to deal with Cordis’s operational challenges, including “implementing new process[es] and technology improvements that will better manage our Cordis consigned inventory.” (/d.). Cardinal also announced its expectation that “operational challenges with Cordis will continue through Q4 and fiscal °19.” (id). The Compiaint alleges that these circumstances caused Cardinal’s stock to decline dramatically, resulting in significant losses for several investors. B. Procedure, On August 1, 2019, Louisiana Sheriffs Pension & Relief Fund (“Louisiana Sheriffs’”) filed class action complaint against Cardinal pursuant to the Sections 10(b) and 20(a) of the Exchange Act (15 U.S.C. §§ 78j(b), 78t(a)), and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder (17 C.F.R.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re American Medical Systems, Inc. Pfizer, Inc.
75 F.3d 1069 (Sixth Circuit, 1996)
In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
In re Vicuron Pharmaceuticals, Inc. Securities Litigation
225 F.R.D. 508 (E.D. Pennsylvania, 2004)
In re Cardinal Health, Inc.
226 F.R.D. 298 (S.D. Ohio, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
Louisiana Sheriffs Pension & Relief Fund v. Cardinal Health, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/louisiana-sheriffs-pension-relief-fund-v-cardinal-health-inc-ohsd-2020.